genOway Société anonyme (ALGEN.PA)
EUR 3.13
(9.65%)
EUR 3.13
(9.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 20.1 Million EUR | 1634.22% |
| 2022 | -1.31 Million EUR | 65.03% |
| 2021 | -3.74 Million EUR | -26.57% |
| 2020 | -2.95 Million EUR | -136.28% |
| 2019 | 8.15 Million EUR | -5.24% |
| 2018 | 8.61 Million EUR | 16.7% |
| 2017 | 7.37 Million EUR | 12.08% |
| 2016 | 6.58 Million EUR | 12.05% |
| 2015 | 5.87 Million EUR | 7.5% |
| 2014 | 5.46 Million EUR | 8.14% |
| 2013 | 5.05 Million EUR | -32.55% |
| 2012 | 7.49 Million EUR | 10.24% |
| 2011 | 6.79 Million EUR | 94.69% |
| 2010 | 3.49 Million EUR | 44.98% |
| 2009 | 2.4 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.71 Million EUR | 0.0% |
| 2023 FY | 20.1 Million EUR | 1634.22% |
| 2023 Q2 | -397.55 Thousand EUR | 0.0% |
| 2023 Q4 | 10.76 Million EUR | 0.0% |
| 2022 FY | -1.31 Million EUR | 65.03% |
| 2022 Q4 | -274.27 Thousand EUR | 0.0% |
| 2022 Q2 | -1.03 Million EUR | 0.0% |
| 2021 Q4 | -1.58 Million EUR | 0.0% |
| 2021 FY | -3.74 Million EUR | -26.57% |
| 2021 Q2 | -2.16 Million EUR | 0.0% |
| 2020 Q2 | -2.19 Million EUR | 0.0% |
| 2020 Q4 | -769.6 Thousand EUR | 0.0% |
| 2020 FY | -2.95 Million EUR | -136.28% |
| 2019 Q2 | 3.22 Million EUR | 0.0% |
| 2019 Q4 | -1.34 Million EUR | 0.0% |
| 2019 FY | 8.15 Million EUR | -5.24% |
| 2018 Q2 | 4.18 Million EUR | 0.0% |
| 2018 FY | 8.61 Million EUR | 16.7% |
| 2018 Q4 | 4.42 Million EUR | 0.0% |
| 2017 Q2 | 4.02 Million EUR | 0.0% |
| 2017 FY | 7.37 Million EUR | 12.08% |
| 2017 Q4 | 3.14 Million EUR | 0.0% |
| 2016 Q4 | 3.71 Million EUR | 0.0% |
| 2016 Q2 | 2.87 Million EUR | 0.0% |
| 2016 FY | 6.58 Million EUR | 12.05% |
| 2015 Q2 | 3 Million EUR | 0.0% |
| 2015 Q4 | 2.86 Million EUR | 0.0% |
| 2015 FY | 5.87 Million EUR | 7.5% |
| 2014 Q4 | 2.72 Million EUR | 0.0% |
| 2014 FY | 5.46 Million EUR | 8.14% |
| 2014 Q2 | 2.73 Million EUR | 0.0% |
| 2013 Q2 | 2.51 Million EUR | 0.0% |
| 2013 Q4 | 2.53 Million EUR | 0.0% |
| 2013 FY | 5.05 Million EUR | -32.55% |
| 2012 Q3 | 699.85 Thousand EUR | -0.0% |
| 2012 Q1 | 699.85 Thousand EUR | -0.0% |
| 2012 Q4 | 687.39 Thousand EUR | -1.78% |
| 2012 FY | 7.49 Million EUR | 10.24% |
| 2012 Q2 | 699.85 Thousand EUR | 0.0% |
| 2011 Q3 | 832.85 Thousand EUR | 0.0% |
| 2011 FY | 6.79 Million EUR | 94.69% |
| 2011 Q4 | 699.85 Thousand EUR | -15.97% |
| 2011 Q2 | 832.85 Thousand EUR | 0.0% |
| 2011 Q1 | 832.85 Thousand EUR | 0.0% |
| 2010 Q1 | 872.66 Thousand EUR | 0.0% |
| 2010 Q4 | 832.85 Thousand EUR | -4.56% |
| 2010 FY | 3.49 Million EUR | 44.98% |
| 2010 Q3 | 872.66 Thousand EUR | 0.0% |
| 2010 Q2 | 872.66 Thousand EUR | 0.0% |
| 2009 FY | 2.4 Million EUR | 0.0% |
| 2009 Q1 | 601.9 Thousand EUR | -0.0% |
| 2009 Q4 | 872.66 Thousand EUR | 44.98% |
| 2009 Q3 | 601.9 Thousand EUR | -0.0% |
| 2009 Q2 | 601.9 Thousand EUR | 0.0% |
| 2008 Q4 | 601.9 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -3152.489% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -413.551% |
| Adocia SA | 1.38 Million EUR | -1351.291% |
| Aelis Farma SA | 12.35 Million EUR | -62.651% |
| Biophytis S.A. | -803 Thousand EUR | 2603.161% |
| Advicenne S.A. | 1.42 Million EUR | -1309.564% |
| IntegraGen SA | 5.01 Million EUR | -300.543% |
| Medesis Pharma S.A. | -2.66 Million EUR | 854.301% |
| Neovacs S.A. | 29.31 Thousand EUR | -68469.223% |
| NFL Biosciences SA | -56.06 Thousand EUR | 35952.565% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -833.635% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 1516.229% |
| Sensorion SA | 3.78 Million EUR | -430.652% |
| Theranexus Société Anonyme | -4.63 Million EUR | 533.32% |
| TME Pharma N.V. | -127 Thousand EUR | 15927.072% |
| Valbiotis SA | 2.66 Million EUR | -653.388% |
| TheraVet SA | -530.79 Thousand EUR | 3886.838% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -1486.455% |
| DBV Technologies S.A. | 4.15 Million EUR | -383.23% |
| Genfit S.A. | 28.22 Million EUR | 28.783% |
| GeNeuro SA | -293.8 Thousand EUR | 6941.519% |
| Innate Pharma S.A. | -4.12 Million EUR | 587.755% |
| Inventiva S.A. | 17.5 Million EUR | -14.859% |
| MaaT Pharma SA | 1.65 Million EUR | -1114.525% |
| MedinCell S.A. | 9.28 Million EUR | -116.412% |
| Nanobiotix S.A. | 36.2 Million EUR | 44.486% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -802.577% |
| Poxel S.A. | 1000.00 EUR | -2009938.2% |
| GenSight Biologics S.A. | 3 Million EUR | -570.013% |
| Transgene SA | -28.4 Million EUR | 170.766% |
| Valneva SE | 52.83 Million EUR | 61.958% |